PRMEPrime Medicine, Inc.vs its industry peers
A metric-by-metric comparison of Prime Medicine, Inc. against SIC 2836 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Empresa | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PRMEEsta | $546M#3 | — | 13.7x#9 | 117.9x#4 | 55.3%#2 | -2.7%#6 | -4498.1%#4 | -505.3%#9 | — | — | -35.5%#2 | — |
| SANA | $918M#1 | — | 5.9x#7 | — | — | 8.5%#4 | — | -158.0%#7 | — | — | — | — |
| ALLO | $591M#2 | — | 1.4x#3 | — | -100.0%#5 | 25.9%#2 | — | -43.8%#4 | — | — | — | — |
| RGNX | $518M#4 | — | 7.2x#8 | 3.0x#2 | 104.5%#1 | 14.6%#3 | -94.6%#1 | -270.2%#8 | — | — | — | — |
| DNA | $459M#5 | — | 1.1x#1 | 2.7x#1 | -25.1%#4 | 42.8%#1 | -185.3%#2 | -0.1%#1 | — | — | -32.1%#1 | — |
| CABA | $433M#6 | — | 2.1x#5 | — | — | -44.9%#9 | — | -79.7%#5 | — | — | — | — |
| KYTX | $432M#7 | — | 2.6x#6 | — | — | -26.5%#7 | — | -97.4%#6 | -107.1%#1 | — | — | — |
| CCCC | $429M#8 | — | 1.7x#4 | 11.9x#3 | 1.0%#3 | 0.3%#5 | -320.5%#3 | -42.5%#3 | — | — | — | — |
| ARTV | $426M#9 | — | 1.2x#2 | — | -100.0%#5 | -28.3%#8 | — | -24.1%#2 | — | — | — | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2836). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. Esta tabla agotó el tiempo durante su construcción, por lo que cubre parte del grupo; los rangos son solo dentro de las filas mostradas y se completará en breve. Table built 2026-09-16.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice